Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T17:55:34.254Z.
Calculation as of: 2026-10-06T17:55:34.254Z.
Quote observation: 2026-10-06T17:54:35.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$763.61M
EV/EBIT Ratio
37.12x
TTM Avg
38.85x
3Y Avg
65.92x
5Y Avg
138.61x
Market Cap
$772.90M
EV/EBIT Ratio
N/A
TTM Avg
15.22x
3Y Avg
6.50x
5Y Avg
6.50x
Market Cap
$778.43M
EV/EBIT Ratio
14.58x
TTM Avg
14.71x
3Y Avg
18.13x
5Y Avg
17.67x
Market Cap
$789.07M
EV/EBIT Ratio
N/A
TTM Avg
957.13x
3Y Avg
957.13x
5Y Avg
957.13x
Market Cap
$786.00M
EV/EBIT Ratio
N/A
TTM Avg
103.45x
3Y Avg
72.64x
5Y Avg
72.64x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Apnimed, Inc. (APMD) | $763.81M | N/A | N/A | N/A | N/A |
| Mesa Laboratories, Inc. (MLAB)vs › | $763.61M | 37.12x | 38.85x | 65.92x | 138.61x |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $772.90M | N/A | 15.22x | 6.50x | 6.50x |
| Sana Biotechnology, Inc. (SANA)vs › | $772.26M | N/A | N/A | N/A | N/A |
| Attovia Therapeutics, Inc. (ATTO)vs › | $768.52M | N/A | N/A | N/A | N/A |
| Varex Imaging Corporation (VREX)vs › | $778.43M | 14.58x | 14.71x | 18.13x | 17.67x |
| Geron Corporation (GERN)vs › | $789.07M | N/A | 957.13x | 957.13x | 957.13x |
| Gyre Therapeutics, Inc. (GYRE)vs › | $786.00M | N/A | 103.45x | 72.64x | 72.64x |
| Design Therapeutics, Inc. (DSGN)vs › | $745.43M | N/A | N/A | N/A | N/A |
| AdaptHealth Corp. (AHCO)vs › | $788.22M | N/A | 13.71x | 14.97x | 19.98x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
